Last reviewed · How we verify

i.v. iron sucrose

J. Uriach and Company · FDA-approved active Small molecule

i.v. iron sucrose is a Iron replacement agent Small molecule drug developed by J. Uriach and Company. It is currently FDA-approved for Iron deficiency anemia in patients with chronic kidney disease on hemodialysis, Iron deficiency anemia in patients with chronic kidney disease not on dialysis, Iron deficiency anemia in patients with non-dialysis-dependent chronic kidney disease.

Iron sucrose is a stable iron-carbohydrate complex that delivers iron directly into the bloodstream to replenish depleted iron stores and support hemoglobin synthesis.

Iron sucrose is a stable iron-carbohydrate complex that delivers iron directly into the bloodstream to replenish depleted iron stores and support hemoglobin synthesis. Used for Iron deficiency anemia in patients with chronic kidney disease on hemodialysis, Iron deficiency anemia in patients with chronic kidney disease not on dialysis, Iron deficiency anemia in patients with non-dialysis-dependent chronic kidney disease.

At a glance

Generic namei.v. iron sucrose
SponsorJ. Uriach and Company
Drug classIron replacement agent
ModalitySmall molecule
Therapeutic areaHematology
PhaseFDA-approved

Mechanism of action

Iron sucrose consists of iron(III) hydroxide bonded to sucrose, forming a stable complex that can be administered intravenously without the tissue toxicity associated with free iron. Once in circulation, the iron is transferred to transferrin and other iron-binding proteins for transport to bone marrow and other tissues, where it is incorporated into hemoglobin and other iron-dependent proteins. This mechanism bypasses gastrointestinal absorption limitations and is particularly useful in patients with chronic kidney disease who cannot tolerate or absorb oral iron adequately.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about i.v. iron sucrose

What is i.v. iron sucrose?

i.v. iron sucrose is a Iron replacement agent drug developed by J. Uriach and Company, indicated for Iron deficiency anemia in patients with chronic kidney disease on hemodialysis, Iron deficiency anemia in patients with chronic kidney disease not on dialysis, Iron deficiency anemia in patients with non-dialysis-dependent chronic kidney disease.

How does i.v. iron sucrose work?

Iron sucrose is a stable iron-carbohydrate complex that delivers iron directly into the bloodstream to replenish depleted iron stores and support hemoglobin synthesis.

What is i.v. iron sucrose used for?

i.v. iron sucrose is indicated for Iron deficiency anemia in patients with chronic kidney disease on hemodialysis, Iron deficiency anemia in patients with chronic kidney disease not on dialysis, Iron deficiency anemia in patients with non-dialysis-dependent chronic kidney disease.

Who makes i.v. iron sucrose?

i.v. iron sucrose is developed and marketed by J. Uriach and Company (see full J. Uriach and Company pipeline at /company/j-uriach-and-company).

What drug class is i.v. iron sucrose in?

i.v. iron sucrose belongs to the Iron replacement agent class. See all Iron replacement agent drugs at /class/iron-replacement-agent.

What development phase is i.v. iron sucrose in?

i.v. iron sucrose is FDA-approved (marketed).

What are the side effects of i.v. iron sucrose?

Common side effects of i.v. iron sucrose include Hypotension, Headache, Nausea, Vomiting, Abdominal pain, Injection site reactions.

Related